Genetix Pharmaceuticals Inc
Genetix Pharmaceuticals Inc is listed today as Bluebird Bio, Inc.: market value, financials and filings are on its company page.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2021 | $75 M | No. 4 | $50 to $250 million | equity | SEC | |
| Jul 2012 | $60 M | No. 3 | $50 to $250 million | equity | SEC | |
| Apr 2011 | $15 M | No. 2 | $10 to $50 million | equity | SEC | |
| Mar 2010 | $38 M | No. 1 | $10 to $50 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Genetix Pharmaceuticals Inc chose not to state its revenue in its newest notice of a funding round (Sep 2021).
SEC Form D · Sep 2021
The industry group it chose in its notices: Biotechnology.
SEC Form D · Sep 2021
That is all the official record says: Genetix Pharmaceuticals Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Genetix Pharmaceuticals Inc are on record.
Investors#
8 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Arch Venture Fund VII LP | Venture capital | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| ARCH Venture Partners VII, LLC | Venture capital | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| ARCH Venture Partners VII, L.P. | Venture capital | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Third Rock Ventures GP, L.P. | Venture capital | not stated | not stated | Held Series B, C and D preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| Third Rock Ventures LP | Venture capital | not stated | not stated | Held Series B, C and D preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| TRV GP, LLC | Other | not stated | not stated | Held Series B, C and D preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| TVM Capital GmbH | Fund or asset manager | not stated | not stated | Held Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
| TVM V Life Science Ventures Gmbh & Co KG | Venture capital | not stated | not stated | Held Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2013) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 17 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Chip Baird | Executive officer | Sep 2021 |
| Jason Cole | Executive officer | Sep 2021 |
| Nick S. Leschly | Executive officer | Sep 2021 |
| Jeffrey T. Walsh | Executive officer | Jul 2012 |
| Nick Leschly | Executive officer | Jul 2012 |
| Daniel S. Lynch | Director | Sep 2021 |
| Denice R. Torres | Director | Sep 2021 |
| John S. Agwunobi | Director | Sep 2021 |
| Mark R. Vachon | Director | Sep 2021 |
| Nick S. Leschly | Director | Sep 2021 |
| Ramy S. Ibrahim | Director | Sep 2021 |
| Wendy S. Dixon | Director | Sep 2021 |
| William R. Sellers | Director | Sep 2021 |
| Axel Polack | Director | Jul 2012 |
| Geert-Jan Mulder | Director | Jul 2012 |
| John M. Maraganore | Director | Jul 2012 |
| Nick Leschly | Director | Jul 2012 |
| Robert Tepper | Director | Jul 2012 |
| Steven Gillis | Director | Jul 2012 |
| Geert-Jan A. Mulder | Director | Mar 2010 |
| James A. Geraghty | Director | Mar 2010 |
About
Company in Cambridge, United States.